Skip to main content

Advertisement

SpringerLink
Log in

Chagas Cardiomyopathy in Latin America Review

  • Heart Failure (HJ Eisen, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Chagas cardiomyopathy is a major public health disease in Latin America and, due to migration, is becoming a worldwide health and economic burden. This review sought to present the clinical and epidemiological aspects of Chagas cardiomyopathy, as well as some specific features and principles of treatment. We also retrospectively assessed our institutional experience with mechanical circulatory support in refractory heart failure due to Chagas cardiomyopathy over a 10-year period.

Recent Findings

The role of antiparasitic treatment in patients with heart failure due to Chagas cardiomyopathy is controversial. Heart transplantation, although formerly contraindicated, is currently established as an important therapeutic option. Also, the favorable characteristics of Chagas patients, such as younger age, little comorbidity, and no reoperations or severe pulmonary hypertension, could be an advantage for a mechanical circulatory support indication in advanced heart failure due to Chagas cardiomyopathy.

Summary

Despite the absence of large evidence-based data, much has been accomplished since Carlos Chagas’ discovery one century ago. Our institutional experience shows that mechanical circulatory support in Chagas patients is associated with more successful bridging to heart transplantation when compared to non-Chagas patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bestetti RB, Restini CB, Couto LB. Carlos Chagas discoveries as a drop back to scientific construction of chronic Chagas heart disease. Arq Bras Cardiol. 2016;107(1):63–70.

    PubMed  PubMed Central  Google Scholar 

  2. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Arq Bras Cardiol. 2011;97(2 Suppl 3):1–48.

    PubMed  Google Scholar 

  3. Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, Edwards MS, et al. Chagas disease: “the new HIV/AIDS of the Americas”. PLoS Negl Trop Dis. 2012;6(5):e1498.

    PubMed  PubMed Central  Google Scholar 

  4. Kalil-Filho R. Globalization of Chagas disease burden and new treatment perspectives. J Am Coll Cardiol. 2015;66(10):1190–2.

    PubMed  Google Scholar 

  5. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13(4):342–8.

    PubMed  PubMed Central  Google Scholar 

  6. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298(18):2171–81.

    CAS  PubMed  Google Scholar 

  7. Benziger CP, do Carmo GA, Ribeiro AL. Chagas cardiomyopathy: clinical presentation and management in the Americas. Cardiol Clin. 2017;35(1):31–47.

    PubMed  Google Scholar 

  8. Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388–402.

    PubMed  Google Scholar 

  9. Robertson LJ, Devleesschauwer B, Alarcón de Noya B, Noya González O, Torgerson PR. Trypanosoma cruzi: time for international recognition as a foodborne parasite. PLoS Negl Trop Dis. 2016;10(6):e0004656.

    PubMed  PubMed Central  Google Scholar 

  10. Cevallos AM, Hernández R. Chagas’ disease: pregnancy and congenital transmission. Biomed Res Int. 2014;2014:401864.

    PubMed  PubMed Central  Google Scholar 

  11. World Health Organization. (2018). Chagas disease (American trypanosomiasis), 2018. Retrieved from http://www.who.int/chagas/epidemiology/en/. Accessed 8 Aug 2018.

  12. • Benatti RD, Al-Kindi SG, Bacal F, Oliveira GH. Heart transplant outcomes in patients with Chagas cardiomyopathy in the United States. Clin Transplant. 2018;32:e13279 This study provides an up-to-date review on heart transplant outcomes in patients with Chagas cardiomyopathy.

    PubMed  Google Scholar 

  13. •• Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017;70(12):1510–24 This study provides a thorough description of Chagas cardiomyopathy treatment.

    PubMed  Google Scholar 

  14. LiÚni KCF, Bavia L, Ambrosio AR, de Messias-Reason IJ. The complement system: a prey of Trypanosoma cruzi. Front Microbiol. 2017;8:607.

    Google Scholar 

  15. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63(3–4):111–8.

    CAS  PubMed  Google Scholar 

  16. Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL, Cardiology CoCDotISo. Chagas disease: an overview of clinical and epidemiological aspects. J Am Coll Cardiol. 2013;62(9):767–76.

    PubMed  Google Scholar 

  17. Souza DH, Vaz MG, Fonseca CR, Luquetti A, Rezende Filho J, Oliveira EC. Current epidemiological profile of Chagasic megaesophagus in Central Brazil. Rev Soc Bras Med Trop. 2013;46(3):316–21.

    PubMed  Google Scholar 

  18. Cunha-Neto E, Chevillard C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediat Inflamm. 2014;2014:683230.

    Google Scholar 

  19. Mocelin AO, Issa VS, Bacal F, Guimarães GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas’ heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2005;7(5):869–73.

    CAS  PubMed  Google Scholar 

  20. Bocchi EA. Update on indications and results of the surgical treatment of heart failure. Arq Bras Cardiol. 1994;63(6):523–30.

    CAS  PubMed  Google Scholar 

  21. Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, Rassi GG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355(8):799–808.

    CAS  PubMed  Google Scholar 

  22. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int J Cardiol. 2005;102(2):239–47.

    PubMed  Google Scholar 

  23. Abuhab A, Trindade E, Aulicino GB, Fujii S, Bocchi EA, Bacal F. Chagas’ cardiomyopathy: the economic burden of an expensive and neglected disease. Int J Cardiol. 2013;168(3):2375–80.

    PubMed  Google Scholar 

  24. Barbosa AP, Cardinalli Neto A, Otaviano AP, Rocha BF, Bestetti RB. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq Bras Cardiol. 2011;97(6):517–25.

    PubMed  Google Scholar 

  25. Martinelli Filho M, De Siqueira SF, Moreira H, Fagundes A, Pedrosa A, Nishioka SD, et al. Probability of occurrence of life-threatening ventricular arrhythmias in Chagas’ disease versus non-Chagas’ disease. Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1944–6.

    CAS  PubMed  Google Scholar 

  26. Bestetti RB, Cardinalli-Neto A. Sudden cardiac death in Chagas’ heart disease in the contemporary era. Int J Cardiol. 2008;131(1):9–17.

    PubMed  Google Scholar 

  27. Ribeiro AL, Rocha MO. Indeterminate form of Chagas disease: considerations about diagnosis and prognosis. Rev Soc Bras Med Trop. 1998;31(3):301–14.

    CAS  PubMed  Google Scholar 

  28. Seiringer P, Pritsch M, Flores-Chavez M, Marchisio E, Helfrich K, Mengele C, et al. Comparison of four PCR methods for efficient detection of Trypanosoma cruzi in routine diagnostics. Diagn Microbiol Infect Dis. 2017;88(3):225–32.

    CAS  PubMed  Google Scholar 

  29. Traina MI, Hernandez S, Sanchez DR, Dufani J, Salih M, Abuhamidah AM, et al. Prevalence of Chagas disease in a U.S. population of Latin American immigrants with conduction abnormalities on electrocardiogram. PLoS Negl Trop Dis. 2017;11(1):e0005244.

    PubMed  PubMed Central  Google Scholar 

  30. Maguire JH, Hoff R, Sherlock I, Guimarães AC, Sleigh AC, Ramos NB, et al. Cardiac morbidity and mortality due to Chagas’ disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987;75(6):1140–5.

    CAS  PubMed  Google Scholar 

  31. Ribeiro AL, Sabino EC, Marcolino MS, Salemi VM, Ianni BM, Fernandes F, et al. Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors. PLoS Negl Trop Dis. 2013;7(2):e2078.

    PubMed  PubMed Central  Google Scholar 

  32. Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115(9):1101–8.

    PubMed  Google Scholar 

  33. Pazin-Filho A, Romano MM, Almeida-Filho OC, Furuta MS, Viviani LF, Schmidt A, et al. Minor segmental wall motion abnormalities detected in patients with Chagas’ disease have adverse prognostic implications. Braz J Med Biol Res. 2006;39(4):483–7.

    CAS  PubMed  Google Scholar 

  34. Acquatella H. Echocardiography in Chagas heart disease. Circulation. 2007;115(9):1124–31.

    PubMed  Google Scholar 

  35. Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart. 2004;90(6):655–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Barros MV, da Costa Rocha MO, Ribeiro AL, Machado FS. Tissue Doppler imaging enables the identification of diastolic dysfunction of pseudonormal pattern in Chagas’ disease. J Am Soc Echocardiogr. 2001;14(5):353–9.

    CAS  PubMed  Google Scholar 

  37. Garcia-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, Ortiz-Pérez JT, Heras M, Azqueta M, Gascon J, Sanz G. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl Trop Dis 2010;4(9). https://doi.org/10.1371/journal.pntd.0000826.

  38. Keating SM, Deng X, Fernandes F, Cunha-Neto E, Ribeiro AL, Adesina B, et al. Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease. Int J Cardiol. 2015;199:451–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Sherbuk JE, Okamoto EE, Marks MA, Fortuny E, Clark EH, Galdos-Cardenas G, et al. Biomarkers and mortality in severe Chagas cardiomyopathy. Glob Heart. 2015;10(3):173–80.

    PubMed  PubMed Central  Google Scholar 

  40. Chatelain E. Chagas disease research and development: is there light at the end of the tunnel? Comput Struct Biotechnol J. 2017;15:98–103.

    PubMed  Google Scholar 

  41. Bestetti RB, Cardinalli-Neto A. Device therapy in Chagas disease heart failure. Expert Rev Cardiovasc Ther. 2012;10(10):1307–17.

    CAS  PubMed  Google Scholar 

  42. Malik LH, Singh GD, Amsterdam EA. The epidemiology, clinical manifestations, and management of Chagas heart disease. Clin Cardiol. 2015;38(9):565–9.

    PubMed  Google Scholar 

  43. Araújo EF, Chamlian EG, Peroni AP, Pereira WL, Gandra SM, Rivetti LA. Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up. Rev Bras Cir Cardiovasc. 2014;29(1):31–6.

    PubMed  PubMed Central  Google Scholar 

  44. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3(1):82–8.

    CAS  PubMed  Google Scholar 

  45. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94.

    PubMed  Google Scholar 

  46. Marin-Neto JA, Rassi A, Avezum A, Mattos AC, Morillo CA, Sosa-Estani S, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):319–24.

    CAS  PubMed  Google Scholar 

  47. • Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized trial of Benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–306 The BENEFIT is the largest randomized trial on Chagas disease.

    CAS  PubMed  Google Scholar 

  48. Rassi A, Marin JA. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole evaluation for interrupting trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz. 2017;112(3):224–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–908.

    PubMed  Google Scholar 

  50. Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, et al. Benznidazole and Posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol. 2017;69(8):939–47.

    CAS  PubMed  Google Scholar 

  51. Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419–30.

    CAS  PubMed  Google Scholar 

  52. Bocchi E. Chagas disease cardiomyopathy treatment remains a challenge. Lancet. 2018;391(10136):2209.

    PubMed  Google Scholar 

  53. Pérez-Molina JA, Molina I. Chagas disease cardiomyopathy treatment remains a challenge – Authors’ reply. Lancet. 2018;391(10136):2209–10.

    PubMed  Google Scholar 

  54. • Kransdorf EP, Fishbein MC, Czer LS, Patel JK, Velleca A, Tazelaar HD, et al. Pathology of chronic Chagas cardiomyopathy in the United States: a detailed review of 13 cardiectomy cases. Am J Clin Pathol. 2016;146(2):191–8 This study provides information on Chagas cardiomyopathy anatomopathology.

    CAS  PubMed  Google Scholar 

  55. Souza JD, Torres A, Mejia JA, Fernandes JR, Vasconcelos GG, Pessoa V, et al. Allograft pathology in patients transplanted in a reference center, including cases of Chagas cardiomyopathy. Eur J Heart Fail Suppl. 2013;12:S73–S325. https://doi.org/10.1093/eurjhf/hst009.

    Google Scholar 

  56. Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13(12):3262–8.

    CAS  PubMed  Google Scholar 

  57. Benatti RD, Oliveira GH, Bacal F. Heart transplantation for Chagas cardiomyopathy. J Heart Lung Transplant. 2017;36(6):597–603.

    PubMed  Google Scholar 

  58. Fiorelli AI, Santos RH, Oliveira JL, Lourenço-Filho DD, Dias RR, Oliveira AS, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc. 2011;43(1):220–4.

    CAS  PubMed  Google Scholar 

  59. Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients with end-stage Chagas’ heart disease. J Card Fail. 2009;15(3):249–55.

    PubMed  Google Scholar 

  60. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71(6):1833–8.

    CAS  PubMed  Google Scholar 

  61. Mangini S, Alves BR, Silvestre OM, Pires PV, Pires LJ, Curiati MN, et al. Heart transplantation: review. Einstein (Sao Paulo). 2015;13(2):310–8.

    Google Scholar 

  62. Bocchi EA. Heart transplants for patients with Chagas’ heart disease. Sao Paulo Med J. 1995;113(2):873–9.

    CAS  PubMed  Google Scholar 

  63. Bocchi EA, Fiorelli A, Cardiology FGGfHTotBSo. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant. 2001;20(6):637–45.

    CAS  PubMed  Google Scholar 

  64. Nogueira SS, Felizardo AA, Caldas IS, Gonçalves RV, Novaes RD. Challenges of immunosuppressive and antitrypanosomal drug therapy after heart transplantation in patients with chronic Chagas disease: a systematic review of clinical recommendations. Transplant Rev (Orlando). 2018;32:157–67.

    Google Scholar 

  65. Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, et al. Risk factors for Chagas’ disease reactivation after heart transplantation. J Heart Lung Transplant. 2008;27(6):597–602.

    PubMed  Google Scholar 

  66. Bacal F, Silva CP, Bocchi EA, Pires PV, Moreira LF, Issa VS, et al. Mychophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant. 2005;5(8):2017–21.

    CAS  PubMed  Google Scholar 

  67. Fiorelli AI, Stolf NA, Honorato R, Bocchi E, Bacal F, Uip D, et al. Later evolution after cardiac transplantation in Chagas’ disease. Transplant Proc. 2005;37(6):2793–8.

    CAS  PubMed  Google Scholar 

  68. Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis. 2014;27(5):418–24.

    PubMed  Google Scholar 

  69. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant. 2011;11(4):672–80.

    CAS  PubMed  Google Scholar 

  70. Schwartz BS, Mawhorter SD, Practice AIDCo. Parasitic infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):280–303.

    CAS  PubMed  Google Scholar 

  71. Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med. 2011;364(26):2527–34.

    CAS  PubMed  Google Scholar 

  72. Moreira LP, Galantier J, Benicio A, Leirner AA, Fiorelli AI, Stolf NAG, et al. Clinical perspectives of patients with Chagas cardiomyopathy listed as high priority for heart transplantation. Braz J Cardiovasc Surg. 2005;20(3):261–9.

    Google Scholar 

  73. Leirner AA, Moreira LF, Stolf NA. The role of circulatory assistance and heart transplantation in Chagas’ disease cardiomyopathy. Artif Organs. 2007;31(4):245–8.

    PubMed  Google Scholar 

  74. Moreira LF, Galantier J, Benício A, Leirner AA, Cestari IA, Stolf NA. Left ventricular circulatory support as bridge to heart transplantation in Chagas’ disease cardiomyopathy. Artif Organs. 2007;31(4):253–8.

    PubMed  Google Scholar 

  75. Ruzza A, Czer LS, De Robertis M, Luthringer D, Moriguchi J, Kobashigawa J, et al. Total artificial heart as bridge to heart transplantation in Chagas cardiomyopathy: case report. Transplant Proc. 2016;48(1):279–81.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Messejana Heart and Lung Hospital Dr. Carlos Alberto Studart Gomes, Av. Frei Cirilo, 3480 Messejana, Fortaleza, CE, 60.846-190, Brazil

    Jefferson Luis Vieira, Fábio Rocha Fernandes Távora, Maria Gyslane Vasconcelos Sobral, Glauber Gean Vasconcelos, Germana Porto Linhares Almeida, Juliana Rolim Fernandes, Laura Leite da Escóssia Marinho, Daniel Francisco de Mendonça Trompieri, João David De Souza Neto & Juan Alberto Cosquillo Mejia

Authors
  1. Jefferson Luis Vieira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fábio Rocha Fernandes Távora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Gyslane Vasconcelos Sobral
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Glauber Gean Vasconcelos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Germana Porto Linhares Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juliana Rolim Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laura Leite da Escóssia Marinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel Francisco de Mendonça Trompieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. João David De Souza Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juan Alberto Cosquillo Mejia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jefferson Luis Vieira.

Ethics declarations

Conflict of Interest

Jefferson Luis Vieira, Fábio Rocha Fernandes Távora, Maria Gyslane Vasconcelos Sobral, Glauber Gean Vasconcelos, Germana Porto Linhares Almeida, Juliana Rolim Fernandes, Laura Leite da Escóssia Marinho, Daniel Francisco de Mendonça Trompieri, João David De Souza Neto, and Juan Alberto Cosquillo Mejia declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vieira, J.L., Távora, F.R.F., Sobral, M.G.V. et al. Chagas Cardiomyopathy in Latin America Review. Curr Cardiol Rep 21, 8 (2019). https://doi.org/10.1007/s11886-019-1095-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-019-1095-y

Keywords

Search

Navigation